FDA Withdraws Three Outdated Electronic Submission Guidances

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Rockville, MD (Sept. 28)-The US Food and Drug Administration has withdrawn three guidances for industry: ?Providing Submissions in Electronic Format?NDAs? (e-NDA), ?Providing Regulatory Submissions in Electronic Format?ANDAs? (e-ANDA), and ?Providing Regulatory Submissions in Electronic Format: Annual Reports for NDAs and ANDAs.? These documents all recommend submitting information as portable document files (PDFs) or as SAS transport files.

Rockville, MD (Sept. 28)-The US Food and Drug Administration (www.fda.gov) has withdrawn three guidances for industry: “Providing Submissions in Electronic Format-NDAs” (e-NDA), “Providing Regulatory Submissions in Electronic Format-ANDAs” (e-ANDA), and “Providing Regulatory Submissions in Electronic Format: Annual Reports for NDAs and ANDAs.” These documents all recommend submitting information as portable document files (PDFs) or as SAS transport files.

Since releasing these guidances in 1999, FDA has adopted the International Conference on Harmonization (ICH) Common Technical Document (CTD), which has an electronic version (e-CTD) that recommends that the table of contents be submitted as an extensible markup language (XML) file instead of as a PDF file. The agency prefers the e-CTD’s XML format, which allows access to “a real-time, up-to-date, cumulative table of contents that provides easy and immediate access to all files included in an application, regardless of when they were included or in what submission they are located,” according to the FDA announcement (http://www.fda.gov/OHRMS/DOCKETS/98fr/99d-0054-nwl0001.pdf). The XML format also allows reviewers to evaluate the application in various discipline-specific views (e.g., clinical aspects for chemistry-related reviews).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes